What is the minimal dose for resistance exercise effectiveness in prostate cancer patients? Systematic review and meta-analysis on patient-reported outcomes.
Journal
Prostate cancer and prostatic diseases
ISSN: 1476-5608
Titre abrégé: Prostate Cancer Prostatic Dis
Pays: England
ID NLM: 9815755
Informations de publication
Date de publication:
06 2021
06 2021
Historique:
received:
28
07
2020
accepted:
04
11
2020
revised:
22
10
2020
pubmed:
22
11
2020
medline:
19
1
2022
entrez:
21
11
2020
Statut:
ppublish
Résumé
Active treatments for prostate cancer are well known to result in several adverse effects such as fatigue, depression and anxiety symptoms, impacting the overall quality of life (QoL) and wellbeing of a considerable proportion of patients. Resistance-based exercise interventions have shown positive effects to reduce or mitigate these treatment-related side effects. However, the minimal dosage required to derive these benefits is unknown. We systematically reviewed the resistance training effects in prostate cancer patients to determine the minimal dosage regarding the exercise components (mode, duration, volume and intensity) on fatigue, QoL, depression and anxiety. Using PRISMA guidelines, MEDLINE, CINAHL, EMBASE, SPORTDiscus and Web of Science databases were searched. Eligible randomised controlled trials examined prostate cancer patients undertaking resistance-based exercise programs during or following treatment. Meta-analysis was undertaken when more than three studies were included. Associations between resistance exercise components and its effects were tested by meta-regression analysis. Eighteen trials involving 1112 men with prostate cancer were included. Resistance-based exercise programs resulted in significant effects on fatigue (effect size = -0.3, 95% CI: -0.4 to -0.2, P < 0.001) and QoL (effect size = 0.2, 95% CI: 0.0 to 0.4, P = 0.018), with significant effects in specific questionnaires and domains of these outcomes. Resistance-based exercise effects on depression (effect size = -0.3, 95% CI: -0.7 to 0.0) and anxiety symptoms (effect size = -0.3, 95% CI: -0.5 to 0.0) were positive but not significant (P = 0.071 to 0.077). Meta-regression indicated no significant association between resistance exercise components with fatigue and QoL outcomes (P = 0.186-0.689). Low volume resistance exercise undertaken at a moderate-to-high intensity is sufficient to achieve significant fatigue and QoL benefits for men with prostate cancer and also mitigate depression and anxiety symptoms. A lower resistance exercise dosage than usually prescribed may help enhance adherence by reducing exercise barriers.
Sections du résumé
BACKGROUND
Active treatments for prostate cancer are well known to result in several adverse effects such as fatigue, depression and anxiety symptoms, impacting the overall quality of life (QoL) and wellbeing of a considerable proportion of patients. Resistance-based exercise interventions have shown positive effects to reduce or mitigate these treatment-related side effects. However, the minimal dosage required to derive these benefits is unknown. We systematically reviewed the resistance training effects in prostate cancer patients to determine the minimal dosage regarding the exercise components (mode, duration, volume and intensity) on fatigue, QoL, depression and anxiety.
METHODS
Using PRISMA guidelines, MEDLINE, CINAHL, EMBASE, SPORTDiscus and Web of Science databases were searched. Eligible randomised controlled trials examined prostate cancer patients undertaking resistance-based exercise programs during or following treatment. Meta-analysis was undertaken when more than three studies were included. Associations between resistance exercise components and its effects were tested by meta-regression analysis.
RESULTS
Eighteen trials involving 1112 men with prostate cancer were included. Resistance-based exercise programs resulted in significant effects on fatigue (effect size = -0.3, 95% CI: -0.4 to -0.2, P < 0.001) and QoL (effect size = 0.2, 95% CI: 0.0 to 0.4, P = 0.018), with significant effects in specific questionnaires and domains of these outcomes. Resistance-based exercise effects on depression (effect size = -0.3, 95% CI: -0.7 to 0.0) and anxiety symptoms (effect size = -0.3, 95% CI: -0.5 to 0.0) were positive but not significant (P = 0.071 to 0.077). Meta-regression indicated no significant association between resistance exercise components with fatigue and QoL outcomes (P = 0.186-0.689).
CONCLUSIONS
Low volume resistance exercise undertaken at a moderate-to-high intensity is sufficient to achieve significant fatigue and QoL benefits for men with prostate cancer and also mitigate depression and anxiety symptoms. A lower resistance exercise dosage than usually prescribed may help enhance adherence by reducing exercise barriers.
Identifiants
pubmed: 33219369
doi: 10.1038/s41391-020-00301-4
pii: 10.1038/s41391-020-00301-4
pmc: PMC8134054
doi:
Types de publication
Journal Article
Meta-Analysis
Research Support, Non-U.S. Gov't
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
465-481Références
D’Amico AV, Chen MH, Renshaw AA, Loffredo M, Kantoff PW. Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial. JAMA. 2008;23:289–95.
Nguyen PL, Alibhai SM, Basaria S, D’Amico AV, Kantoff PW, Keating NL, et al. Adverse effects of androgen deprivation therapy and strategies to mitigate them. Eur Urol. 2015;67:825–36.
doi: 10.1016/j.eururo.2014.07.010
pubmed: 25097095
Storey DJ, McLaren DB, Atkinson MA, Butcher I, Frew LC, Smyth JF, et al. Clinically relevant fatigue in men with hormone-sensitive prostate cancer on long-term androgen deprivation therapy. Ann Oncol. 2012;23:1542–9.
pubmed: 22007078
doi: 10.1093/annonc/mdr447
Dinh KT, Yang DD, Nead KT, Reznor G, Trinh QD, Nguyen PL. Association between androgen deprivation therapy and anxiety among 78 000 patients with localized prostate cancer. Int J Urol. 2017;24:743–8.
pubmed: 28734019
doi: 10.1111/iju.13409
Watts S, Leydon G, Birch B, Prescott P, Lai L, Eardley S, et al. Depression and anxiety in prostate cancer: a systematic review and meta-analysis of prevalence rates. BMJ Open. 2014;4:e003901.
pubmed: 24625637
pmcid: 3963074
doi: 10.1136/bmjopen-2013-003901
Galvão DA, Taaffe DR, Spry N, Joseph D, Newton RU. Combined resistance and aerobic exercise program reverses muscle loss in men undergoing androgen suppression therapy for prostate cancer without bone metastases: a randomized controlled trial. J Clin Oncol. 2010;28:340–7.
pubmed: 19949016
doi: 10.1200/JCO.2009.23.2488
Galvão DA, Spry N, Denham J, Taaffe DR, Cormie P, Joseph D, et al. A multicentre year-long randomised controlled trial of exercise training targeting physical functioning in men with prostate cancer previously treated with androgen suppression and radiation from TROG 03.04 RADAR. Eur Urol. 2014;65:856–64.
pubmed: 24113319
doi: 10.1016/j.eururo.2013.09.041
Taaffe DR, Newton RU, Spry N, Joseph D, Chambers SK, Gardiner RA, et al. Effects of different exercise modalities on fatigue in prostate cancer patients undergoing androgen deprivation therapy: a year-long randomised controlled trial. Eur Urol. 2017;72:293–9.
pubmed: 28249801
doi: 10.1016/j.eururo.2017.02.019
Taaffe DR, Buffart LM, Newton RU, Spry N, Denham J, Joseph D, et al. Time on androgen deprivation therapy and adaptations to exercise: Secondary analysis from a 12-month randomized controlled trial in men with prostate cancer. BJU Int. 2018;121:194–202.
pubmed: 28872752
doi: 10.1111/bju.14008
Cormie P, Galvão DA, Spry N, Joseph D, Chee R, Taaffe DR, et al. Can supervised exercise prevent treatment toxicity in patients with prostate cancer initiating androgen-deprivation therapy: a randomised controlled trial. BJU Int. 2015;115:256–66.
pubmed: 24467669
doi: 10.1111/bju.12646
Livingston PM, Craike MJ, Salmon J, Courneya KS, Gaskin CJ, Fraser SF, et al. Effects of a clinician referral and exercise program for men who have completed active treatment for prostate cancer: a multicenter cluster randomized controlled trial (ENGAGE). Cancer. 2015;121:2646–54.
pubmed: 25877784
doi: 10.1002/cncr.29385
Campbell KL, Winters-Stone KM, Wiskemann J, May AM, Schwartz AL, Courneya KS, et al. Exercise guidelines for cancer survivors: consensus statement from international multidisciplinary roundtable. Med Sci Sports Exerc. 2019;51:2375–90.
pubmed: 31626055
pmcid: 8576825
doi: 10.1249/MSS.0000000000002116
Norris MK, Bell GJ, North S, Courneya KS. Effects of resistance training frequency on physical functioning and quality of life in prostate cancer survivors: a pilot randomized controlled trial. Prostate Cancer Prostatic Dis. 2015;18:281–7.
pubmed: 26078203
doi: 10.1038/pcan.2015.28
Bourke L, Smith D, Steed L, Hooper R, Carter A, Catto J, et al. Exercise for men with prostate cancer: a systematic review and meta-analysis. Eur Urol. 2016;69:693–703.
doi: 10.1016/j.eururo.2015.10.047
pubmed: 26632144
Chen Z, Zhang Y, Lu C, Zeng H, Schumann M, Cheng S. Supervised physical training enhances muscle strength but not muscle mass in prostate cancer patients undergoing androgen deprivation therapy: a systematic review and meta-analysis. Front Physiol. 2019;10:843.
pubmed: 31333495
pmcid: 6618665
doi: 10.3389/fphys.2019.00843
Keilani M, Hasenoehrl T, Baumann L, Ristl R, Schwarz M, Marhold M, et al. Effects of resistance exercise in prostate cancer patients: a meta-analysis. Support Care Cancer. 2017;25:2953–68.
pubmed: 28600706
pmcid: 5527087
doi: 10.1007/s00520-017-3771-z
Yang B, Wang J. Effects of exercise on cancer-related fatigue and quality of life in prostate cancer patients undergoing androgen deprivation therapy: a meta-analysis of randomized clinical trials. Chin Med Sci J. 2017;32:13–21.
pubmed: 28399980
doi: 10.24920/J1001-9242.2007.002
Ying M, Zhao R, Jiang D, Gu S, Li M. Lifestyle interventions to alleviate side effects on prostate cancer patients receiving androgen deprivation therapy: a meta-analysis. Jpn J Clin Oncol. 2018;48:827–34.
pubmed: 30053039
doi: 10.1093/jjco/hyy101
Yunfeng G, Weiyang H, Xueyang H, Yilong H, Xin G. Exercise overcome adverse effects among prostate cancer patients receiving androgen deprivation therapy: an update meta-analysis. Medicine (Baltim). 2017;96:e7368.
doi: 10.1097/MD.0000000000007368
Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JP, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ. 2009;339:b2700.
pubmed: 19622552
pmcid: 2714672
doi: 10.1136/bmj.b2700
Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann T, Mulrow CD, et al. Mapping of reporting guidance for systematic reviews and meta-analyses generated a comprehensive item bank for future reporting guidelines. J Clin Epidemiol. 2020;118:60–68.
pubmed: 31740319
doi: 10.1016/j.jclinepi.2019.11.010
Furlan AD, Pennick V, Bombardier C, van Tulder M, Editorial Board, Cochrane Back Review Group. 2009 updated method guidelines for systematic reviews in the Cochrane Back Review Group. Spine (Philos Pa 1976). 2009;34:1929–41.
doi: 10.1097/BRS.0b013e3181b1c99f
Sterne JAC, Savović J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:l4898.
pubmed: 31462531
doi: 10.1136/bmj.l4898
Yellen SB, Cella DF, Webster K, Blendowski C, Kaplan E. Measuring fatigue and other anemia-related symptoms with the Functional Assessment of Cancer Therapy (FACT) measurement system. J Pain Symptom Manag. 1997;13:63–74.
doi: 10.1016/S0885-3924(96)00274-6
Knobel H, Loge JH, Brenne E, Fayers P, Hjermstad MJ, Kaasa S. The validity of EORTC QLQ-C30 fatigue scale in advanced cancer patients and cancer survivors. Palliat Med. 2003;17:664–72.
pubmed: 14694917
doi: 10.1191/0269216303pm841oa
Stein KD, Jacobsen PB, Blanchard CM, Thors C. Further validation of the multidimensional fatigue symptom inventory-short form. J Pain Symptom Manag. 2004;27:14–23.
doi: 10.1016/j.jpainsymman.2003.06.003
Webster K, Cella D, Yost K. The functional assessment of chronic illness therapy (FACIT) measurement system: Properties, applications, and interpretation. Health Qual Life Outcomes. 2003;1:79.
pubmed: 14678568
pmcid: 317391
doi: 10.1186/1477-7525-1-79
Mendoza T, Wang XS, Cleeland CS, Morrissey M, Johnson BA, Wendt JK, et al. The rapid assessment of fatigue severity in cancer patients: use of the Brief Fatigue Inventory. Cancer. 1999;85:1186–96.
pubmed: 10091805
doi: 10.1002/(SICI)1097-0142(19990301)85:5<1186::AID-CNCR24>3.0.CO;2-N
Schwartz AL. The Schwartz cancer fatigue scale: testing reliability and validity. Oncol Nurs Forum. 1998;25:711–7.
pubmed: 9599354
Esper P, Mo F, Chodak G, Sinner M, Cella D, Pienta KJ. Measuring quality of life in men with prostate cancer using the functional assessment of cancer therapy-prostate instrument. Urology. 1997;50:920–8.
pubmed: 9426724
doi: 10.1016/S0090-4295(97)00459-7
Gandek B, Ware JE. Translating functioning and well-being: international quality of life assessment (IQOLA) project studies of the SF-36 health survey. J Clin Epidemiol. 1998;51:891–1214.
doi: 10.1016/S0895-4356(98)00080-8
Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993;85:365–76.
pubmed: 8433390
doi: 10.1093/jnci/85.5.365
Radloff LS. The CES-D scale: a self-report depression scale for research in the general population. Appl Psychol Meas. 1977;1:385–401.
doi: 10.1177/014662167700100306
Derogatis LR. Brief Symptom Inventory (BSI)-18: Administration, scoring and procedures manual. Minneapolis: NCS Pearson; 2001.
Roth AJ, Rosenfeld B, Kornblith AB, Gibson C, Scher HI, Curley-Smart T, et al. The memorial anxiety scale for prostate cancer: validation of a new scale to measure anxiety in men with with prostate cancer. Cancer. 2003;97:2910–8.
pubmed: 12767107
doi: 10.1002/cncr.11386
Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al. Cochrane handbook for systematic reviews of interventions version 6.0 (updated July 2019). Cochrane, 2019.
DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177–88.
pubmed: 3802833
doi: 10.1016/0197-2456(86)90046-2
Cohen J. Statistical power analysis. Curr Dir Psychol Sci. 1992;1:98–101.
doi: 10.1111/1467-8721.ep10768783
Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557–60.
pubmed: 12958120
pmcid: 192859
doi: 10.1136/bmj.327.7414.557
Peters JL, Sutton AJ, Jones DR, Abrams KR, Rushton L. Contour-enhanced meta-analysis funnel plots help distinguish publication bias from other causes of asymmetry. J Clin Epidemiol. 2008;61:991–6.
pubmed: 18538991
doi: 10.1016/j.jclinepi.2007.11.010
Duval S, Tweedie R. Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics. 2000;56:455–63.
pubmed: 10877304
doi: 10.1111/j.0006-341X.2000.00455.x
Segal RJ, Reid RD, Courneya KS, Malone SC, Parliament MB, Scott CG, et al. Resistance exercise in men receiving androgen deprivation therapy for prostate cancer. J Clin Oncol. 2003;21:1653–9.
pubmed: 12721238
doi: 10.1200/JCO.2003.09.534
Segal RJ, Reid RD, Courneya KS, Sigal RJ, Kenny GP, Prud’Homme DG, et al. Randomized controlled trial of resistance or aerobic exercise in men receiving radiation therapy for prostate cancer. J Clin Oncol. 2009;27:344–51.
pubmed: 19064985
doi: 10.1200/JCO.2007.15.4963
Bourke L, Doll H, Crank H, Daley A, Rosario D, Saxton JM. Lifestyle intervention in men with advanced prostate cancer receiving androgen suppression therapy: a feasibility study. Cancer Epidemiol Biomark Prev. 2011;20:647–57.
doi: 10.1158/1055-9965.EPI-10-1143
Cormie P, Newton RU, Spry N, Joseph D, Taaffe DR, Galvão DA. Safety and efficacy of resistance exercise in prostate cancer patients with bone metastases. Prostate Cancer Prostatic Dis. 2013;16:328–35.
pubmed: 23917308
doi: 10.1038/pcan.2013.22
Bourke L, Gilbert S, Hooper R, Steed LA, Joshi M, Catto JW, et al. Lifestyle changes for improving disease-specific quality of life in sedentary men on long-term androgen-deprivation therapy for advanced prostate cancer: a randomised controlled trial. Eur Urol. 2014;65:865–72.
pubmed: 24119318
doi: 10.1016/j.eururo.2013.09.040
Winters-Stone KM, Dieckmann N, Maddalozzo GF, Bennett JA, Ryan CW, Beer TM. Resistance exercise reduces body fat and insulin during androgen-deprivation therapy for prostate cancer. Oncol Nurs Forum. 2015;42:348–56.
pubmed: 26148314
doi: 10.1188/15.ONF.348-356
Nilsen TS, Raastad T, Skovlund E, Courneya KS, Langberg CW, Lilleby W, et al. Effects of strength training on body composition, physical functioning, and quality of life in prostate cancer patients during androgen deprivation therapy. Acta Oncol. 2015;54:1805–13.
pubmed: 25927504
doi: 10.3109/0284186X.2015.1037008
Winters-Stone KM, Lyons KS, Dobek J, Dieckmann NF, Bennett JA, Nail L, et al. Benefits of partnered strength training for prostate cancer survivors and spouses: results from a randomized controlled trial of the Exercising Together project. J Cancer Surviv. 2016;10:633–44.
pubmed: 26715587
doi: 10.1007/s11764-015-0509-0
Hojan K, Kwiatkowska-Borowczyk E, Leporowska E, Milecki P. Inflammation, cardiometabolic markers, and functional changes in men with prostate cancer. A randomized controlled trial of a 12‑month exercise program. Pol Arch Intern Med. 2017;127:25–35.
pubmed: 28075422
Galvão DA, Taaffe DR, Spry N, Cormie P, Joseph D, Chambers SK, et al. Exercise preserves physical function in prostate cancer patients with bone metastases. Med Sci Sports Exerc. 2018;50:393–9.
pubmed: 29036016
doi: 10.1249/MSS.0000000000001454
Dawson JK, Dorff TB, Todd Schroeder E, Lane CJ, Gross ME, Dieli-Conwright CM. Impact of resistance training on body composition and metabolic syndrome variables during androgen deprivation therapy for prostate cancer: a pilot randomized controlled trial. BMC Cancer. 2018;18:368.
pubmed: 29614993
pmcid: 5883585
doi: 10.1186/s12885-018-4306-9
Alibhai SMH, Santa Mina D, Ritvo P, Tomlinson G, Sabiston C, Krahn M, et al. A phase II randomized controlled trial of three exercise delivery methods in men with prostate cancer on androgen deprivation therapy. BMC Cancer. 2019;19:2.
pubmed: 30606137
pmcid: 6318980
doi: 10.1186/s12885-018-5189-5
Ndjavera W, Orange ST, O’Doherty AF, Leicht AS, Rochester M, Mills R, et al. Exercise-induced attenuation of treatment side-effects in patients with newly diagnosed prostate cancer beginning androgen-deprivation therapy: a randomised controlled trial. BJU Int. 2020;125:28–37.
pubmed: 31605663
doi: 10.1111/bju.14922
Buffart LM, Sweegers MG, May AM, Chinapaw MJ, van Vulpen JK, Newton RU, et al. Targeting exercise interventions to patients with cancer in need: an individual patient data meta-analysis. J Natl Cancer Inst. 2018;110:1190–1200.
pubmed: 30299508
pmcid: 6454466
doi: 10.1093/jnci/djy161
Van Vulpen JK, Sweegers MG, Peeters PHM, Courneya KS, Newton RU, Aaronson NK, et al. Moderators of exercise effects on cancer-related fatigue: a meta-analysis of individual patient data. Med Sci Sports Exerc. 2020;52:303–14.
pmcid: 6962544
doi: 10.1249/MSS.0000000000002154
Hart PD, Buck DJ. The effect of resistance training on health-related quality of life in older adults: systematic review and meta-analysis. Health Promot Perspect. 2019;9:1–12.
pubmed: 30788262
pmcid: 6377696
doi: 10.15171/hpp.2019.01
Cramp F, James A, Lambert J. The effects of resistance training on quality of life in cancer: a systematic literature review and meta-analysis. Support Care Cancer. 2010;18:1367–76.
pubmed: 20502922
doi: 10.1007/s00520-010-0904-z
Sweegers MG, Altenburg TM, Chinapaw MJ, Kalter J, Verdonck-de Leeuw IM, Courneya KS, et al. Which exercise prescriptions improve quality of life and physical function in patients with cancer during and following treatment? A systematic review and meta-analysis of randomised controlled trials. Br J Sports Med. 2018;52:505–13.
pubmed: 28954800
doi: 10.1136/bjsports-2017-097891
Brown JC, Huedo-Medina TB, Pescatello LS, Ryan SM, Pescatello SM, Moker E, et al. The efficacy of exercise in reducing depressive symptoms among cancer survivors: a meta-analysis. PLoS ONE. 2012;7:e30955.
pubmed: 22303474
pmcid: 3267760
doi: 10.1371/journal.pone.0030955
Gordon BR, McDowell CP, Hallgren M, Meyer JD, Lyons M, Herring MP. Association of efficacy of resistance exercise training with depressive symptoms: meta-analysis and meta-regression analysis of randomized clinical trials. JAMA Psychiatry. 2018;75:566–76.
pubmed: 29800984
doi: 10.1001/jamapsychiatry.2018.0572
Gordon BR, McDowell CP, Lyons M, Herring MP. The effects of resistance exercise training on anxiety: a meta-analysis and meta-regression analysis of randomized controlled trials. Sports Med. 2017;47:2521–32.
pubmed: 28819746
doi: 10.1007/s40279-017-0769-0
Lahart IM, Metsios GS, Nevill AM, Carmichael AR. Physical activity for women with breast cancer after adjuvant therapy. Cochrane Database Syst Rev. 2018;1:CD011292.
pubmed: 29376559
Mishra SI, Scherer RW, Snyder C, Geigle PM, Berlanstein DR, Topaloglu O. Exercise interventions on health-related quality of life for people with cancer during active treatment. Cochrane Database Syst Rev. 2012;2012:CD008465.
pmcid: 7389071
Pompe RS, Krüger A, Preisser F, Karakiewicz PI, Michl U, Graefen M, et al. The impact of anxiety and depression on surgical and functional outcomes in patients who underwent radical prostatectomy. Eur Urol Focus. 2018: S2405-4569(18)30410-3.
Hayes SC, Newton RU, Spence RR, Galvão DA. The Exercise and Sports Science Australia position statement: exercise medicine in cancer management. J Sci Med Sport. 2019;22:1175–99.
pubmed: 31277921
doi: 10.1016/j.jsams.2019.05.003
Cella D, Eton DT, Lai JS, Peterman AH, Merkel DE. Combining anchor and distribution-based methods to derive minimal clinically important differences on the Functional Assessment of Cancer Therapy (FACT) anemia and fatigue scales. J Pain Symptom Manag. 2002;24:547–61.
doi: 10.1016/S0885-3924(02)00529-8
Van Belle S, Paridaens R, Evers G, Kerger J, Bron D, Foubert J, et al. Comparison of proposed diagnostic criteria with FACT-F and VAS for cancer-related fatigue: proposal for use as a screening tool. Support Care Cancer. 2005;13:246–54.
pubmed: 15549424
doi: 10.1007/s00520-004-0734-y
Cella D, Lai JS, Chang CH, Peterman A, Slavin M. Fatigue in cancer patients compared with fatigue in the general United States population. Cancer. 2002;94:528–38.
pubmed: 11900238
doi: 10.1002/cncr.10245
Schwartz AL, Meek PM, Nail LM, Fargo J, Lundquist M, Donofrio M, et al. Measurement of fatigue. determining minimally important clinical differences. J Clin Epidemiol. 2002;55:239–44.
pubmed: 11864794
doi: 10.1016/S0895-4356(01)00469-3
Nordin Å, Taft C, Lundgren-Nilsson Å, Dencker A. Minimal important differences for fatigue patient reported outcome measures-a systematic review. BMC Med Res Methodol. 2016;16:62.
pubmed: 27387456
pmcid: 4937582
doi: 10.1186/s12874-016-0167-6
Pearman T, Yanez B, Peipert J, Wortman K, Beaumont J, Cella D. Ambulatory cancer and US general population reference values and cutoff scores for the functional assessment of cancer therapy. Cancer. 2014;120:2902–9.
pubmed: 24853866
doi: 10.1002/cncr.28758
Skaltsa K, Longworth L, Ivanescu C, Phung D, Holmstrom S. Mapping the FACT-P to the preference-based EQ-5D questionnaire in metastatic castration-resistant prostate cancer. Value Health. 2014;17:238–44.
pubmed: 24636382
doi: 10.1016/j.jval.2013.12.005
Osoba D, Rodrigues G, Myles J, Zee B, Pater J. Interpreting the significance of changes in health-related quality of life scores. J Clin Oncol. 1998;16:139–44.
pubmed: 9440735
doi: 10.1200/JCO.1998.16.1.139
Cocks K, King MT, Velikova G, de Castro G Jr, Martyn St-James M, Fayers PM, et al. Evidence-based guidelines for interpreting change scores for the European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30. Eur J Cancer. 2012;48:1713–21.
pubmed: 22418017
doi: 10.1016/j.ejca.2012.02.059
Snyder CF, Blackford AL, Okuyama T, Akechi T, Yamashita H, Toyama T, et al. Using the EORTC-QLQ-C30 in clinical practice for patient management: identifying scores requiring a clinician’s attention. Qual Life Res. 2013;22:2685–91.
pubmed: 23532341
doi: 10.1007/s11136-013-0387-8
Wyrwich KW, Tierney WM, Babu AN, Kroenke K, Wolinsky FD. A comparison of clinically important differences in health-related quality of life for patients with chronic lung disease, asthma, or heart disease. Health Serv Res. 2005;40:577–91.
pubmed: 15762908
pmcid: 1361158
doi: 10.1111/j.1475-6773.2005.0l374.x